Optimizing Drug Delivery Strategies by Pathway Analysis for Waveform Modulation-Based Molecular Communication

Ming Tan[1], Yue Sun[1(✉)], Dongze Wang[1], and Yifan Chen[2]

[1] The School of Mechanical and Electrical Engineering, Chengdu University of Technology, Chengdu 610059, China
sunyuestc90@126.com

[2] The School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610000, China

Abstract. This paper introduces an approach that combines molecular communication (MC) concepts with waveform modulation techniques to regulate drug concentrations at targeted lesion sites, aiming to enhance therapeutic outcomes and minimize side effects. We focus on keeping drug levels within the therapeutic window by grounding our method in MC theory. Our study is primarily the analytical process of selecting the most effective pathways in vascular networks, considering factors such as blood vessel characteristics and the frequency of their branching. This investigation is critical for a deeper understanding of the complexities of the dynamic nature of pathway selection in vascular networks and for seeking to refine drug administration based on these insights. Our research pinpoints the optimal timing for drug administration using continuous-release formulations, ensuring consistent locoregional drug concentrations. The simulations validate our approach, indicating its potential to maintain stable drug levels, thereby underscoring the importance of adapting to variations in the intravascular delivery pathway. Our method, which merges MC principles with waveform modulation, contributes a nuanced perspective on enhancing the precision of drug delivery, supporting the development of an effective and personalized treatment strategy.

Keywords: Target Drug Delivery · Molecular Communication · Vascular Network · Waveforms Modulation · Locoregional Drug Concentration

This work is supported by the National Natural Science Foundation of China (Grants No. 62301088).

Y. Chen et al. (Eds.): BICT 2024, LNICST 592, pp. 11–19, 2025.
https://doi.org/10.1007/978-3-031-81599-7_2

1 Introduction

A novel drug delivery approach aims to transport medications specifically to targeted areas of injury or disease, administering them at carefully regulated doses and rates, all while mitigating any negative impacts on surrounding healthy tissues. [1] A key hurdle is poor efficacy, with only 0.7% of the administered dose effectively reaching the targeted diseased tissues, primarily due to dependence on systemic blood circulation [2]. MC is an emerging paradigm inspired by biological systems in nature, facilitating the exchange of information molecules among biological nanomachines in a fluid environment [3], [6,7], [13]. The parallels between drug delivery and the propagation of information molecules allow for the modeling of the drug delivery process within the frameworks of pharmacokinetics and fluid dynamics, effectively mapping it onto an MC model [1,4,5]. A drug delivery system inspired by MC illustrates the movement of drug particles within vessels and the progression of their distribution over time, which is crucial for regulating the local concentration of the drug. [9,13]. Hence, drug delivery mediated through blood, based on molecular MC principles, emerges as a novel and evolving domain to enhance therapeutic and diagnostic outcomes for tumors in specific regions.

Identifying precise drug delivery methods to target disease sites is a critical focus in targeted drug delivery, crucial for drug efficacy and minimizing side effects. Despite advances in delivery technologies, challenges remain in ensuring accurate delivery and avoiding harm to healthy tissues. Previous work has not focused on the impact of blood vessel length and the frequency of vessel branching on drug concentrations at lesion sites [14]. Factors such as blood flow, vascular structure, and drug properties significantly influence how drugs reach disease sites [15]. Variations in vascular pathways can alter drug concentrations at these sites, affecting treatment outcomes and safety. Therefore, exploring and comparing the effects of different vascular pathways on drug delivery is vital for enhancing delivery precision and effectiveness.

This study examines the influence of vascular pathways on drug concentrations at lesion sites, focusing on how variations in vessel length and branching frequency, as well as the strategy of administering the total drug dose in multiple stages, affect the concentration of drugs at target areas. The research seeks to offer a theoretical basis and practical insights for improving the precision of drug targeting through detailed analysis of drug concentration differences across various delivery routes, aiming to minimize unnecessary side effects and enhance the efficacy of drug delivery strategies. In this context, waveform modulation emerges as a sophisticated method for fine-tuning drug concentrations at targeted lesion sites [14]. By mimicking the natural communication process between biological entities, this method leverages the temporal and spatial modulation of drug release rates to create specific concentration-time profiles—akin to signal waveforms. This approach aims to optimize the therapeutic window by precisely controlling the peak and duration of drug presence within the target area, maximizing efficacy, and minimizing side effects.

The rest of the paper is organized as follows: Sect. 2 presents the blood vessel length and branching patterns model. Section 3 comprises simulation analysis, and Sect. 4 combines the conclusions derived from the simulation.

2 Drug Delivery System Model Derived from MC

According to the MC framework, the pharmacokinetic model for cylindrical and degradable sustained-release agents is illustrated as the process of communication release, Indicated as the input pulse $x_{ti}(t)$ for the i_{th} administration [14].

$$x_{ti}(t) = 2\pi ChB[r - B(t - t_i)] \tag{1}$$

here C represents the dosage per unit area, while h and r denote the height and radius of the cylindrical troche, respectively. B represents the surface degradation rate of the agent. Q_i represents the drug dosage delivered by a sustained-release tablet, represented as [14]

$$Q_i = \int_{t_i}^{t_i + t_{slot}} x_{ti}(t)\, dt \tag{2}$$

here t_i represents the time of the i_{th} administration and t_{slot} refers to the duration of the drug release.

2.1 Vascular System Model

The channel model aligns with the vascular network under advection, characterized described by the advection-diffusion equation [9]:



Fig. 1. The vascular system model grounded in molecular communication

$$\frac{\partial c}{\partial t} + \nabla \cdot (vc) = D\nabla^2 c \tag{3}$$

here v represents the velocity vector, D represents the diffusion coefficient.c is the concentration at a specific location. The vascular network contains multiple bifurcation points, as illustrated in Fig. 1. As drug particles pass through a node, they transition into another section of the channel network. Consequently, the Channel Impulse Response (CIR) of blood vessels at various stages is [9].

$$h_j(t) = \frac{1}{\sqrt{4\pi Dt}} e^{\frac{-(d_j - v_j t)^2}{4Dt}} \qquad j = 1, 2, 3... \tag{4}$$

here d_j is the length and v_j is the advection velocity of the j_{th} stage of the blood vessels.

Based on the evaluation of pharmacokinetic data, a drug's half-life is a crucial reference for proper drug administration, as it is closely related to liver and kidney function in the process of drug elimination [10]. Thus, the CIR is subsequently expressed as

$$H_j(t) = h_j(t)e^{-kt} \qquad j = 1, 2, 3... \tag{5}$$

here k represents the rate of drug elimination. In a particular MC system, the clearance rate is regarded as constant.

2.2 Model for Drug Particle Reception

The reception model explains the progression of locoregional drug concentration at the lesion, accounting for both the channel influences and the degradation of the therapeutic agent. Based on the previously mentioned MC channel model and the drug release rate $x_{ti}(t)$, the drug concentration at the first-order bifurcation point in the vascular system is expressed as follows [14].

$$g_i(t) = x_{t_i}(t) * H_1(t) \quad i = 1, 2, 3 \ldots \tag{6}$$

In a similar manner,$y_{Ri}(t)$ represents the locoregional drug concentration at the lesion:

$$y_{Ri}(t) = \int_{\tau} g_i(\tau) H_2(t - \tau)\, d\tau \tag{7}$$

The total drug concentration over time profile at the lesion,$y_{R(t)}$ is expressed as:

$$y_R(t) = \sum_i y_{Ri}(t) \qquad i = 1, 2, 3... \tag{8}$$

Table 1. PARAMETERS.

Parameters	Symbol	Values
Diffusion coefficient	D	$0.00001\,m^2/s$
Length of vessel	d	$0.1 \sim 5\,m$
Clearance rate constant	k	0.2
Degradation rate constant	B	0.05
Dosage per unit area	C_0	$0.39 \sim 3.54\ g$
Height of cylinder	h	$3\,mm$
Radius of cylinder	r	$3 \sim 9\,mm$



Fig. 2. The concentration of drugs delivered to the lesion site by different routes

3 Results and Analysis of Simulations

This section provides the simulation results of the proposed scheme, utilizing the parameters listed in Table 1 as the default settings. [14].

In medical treatments, achieving the desired therapeutic effect depends on keeping the drug concentration at the target site within a specific range, known as the therapeutic or safety window [11]. Concentrations of the drug exceeding the Minimum Toxic Concentration (MTC) might lead to adverse side effects. In contrast, levels below the Minimum Effective Concentration (MEC) are likely insufficient to yield the desired therapeutic results. Furthermore, inappropriate levels of drug concentration could heighten the risk of patients acquiring resistance to the medication [12].

Path 1, Path 2, and Path 3 correspond respectively to the top blood vessel, the bottom blood vessel, and the middle blood vessel in Fig. 1 In this study,

different vascular pathway models were constructed to simulate the changes in local drug concentration caused by the difference in the pathway during drug arrival at the lesion site. We aimed to assess which pathway would maintain a more stable drug concentration within the drug treatment window between the MTC and MEC. Stabilizing drug concentration within the ideal treatment window helps achieve optimal therapeutic effects and reduce adverse patient reactions.



Fig. 3. the area of the locoregional drug concentration-time curve within the therapeutic windows

Paths path1, path2, and path3 represent three situations in which drugs reach the site of the lesion through different blood vessels. The simulation results are shown in Fig. 2. The drug concentration in each route increased rapidly and then decreased gradually during drug delivery. In particular, for path1 and path2, due to more branches, the time of drug arrival at the lesion site is more dispersed, resulting in a lower and more gradual peak of drug concentration at the lesion site. In contrast, the drug concentration of path3 increased the fastest. However, due to the characteristics of its direct access to the lesion site, the concentration peak was higher, and the rate of decline was faster in the later period.

In Fig. 3, by comparing the concentration-time curves of the three pathways, we observed that the length of time maintained within the treatment window is critical for drug efficacy. Path1 and path2, although the drug concentration rises more slowly, can remain above the MEC for a more extended period, which helps to sustain the treatment effect. Path3, on the other hand, may require more careful adjustment of the delivery interval to avoid the drug's concentration falling out of the treatment window too quickly.



Fig. 4. Drug concentration in the lesion site of multiple drug delivery

The drug is delivered multiple times under different paths, and the drug concentration diagram is shown in Fig. 4. The simulation revealed that after each delivery, the concentration of the drug rose rapidly to its peak and then gradually declined. Throughout three deliveries, the drug concentration curve showed a distinct multi-modal property, indicating that the drug was present at the lesion site for an extended period after each delivery, helping to provide more sustained efficacy. By carefully regulating the delivery interval, we can optimize the concentration curve, reduce fluctuations, and stay within the treatment window.

Paths 1 and 2 reach the lesion site after multiple branches, and the segmentation delivery makes each drug concentration peak more balanced, which helps to avoid drug concentrations that are too high to exceed MTC and prevents the concentration from rapidly falling below MEC. This property is essential to avoid adverse reactions caused by drugs and to maintain a sustained therapeutic effect. On the contrary, the drug delivery speed of the direct path path3 is fast. However, it is easy to cause large dose fluctuations, so segmentation delivery can help smooth these fluctuations and reduce the impact of drug concentration mutations on the lesion.

In Fig. 5, the area of drug concentration within the efficacy window is shown by filling shadows. It can be seen that after proper segmentation delivery, the drug concentration of the three routes has been maintained within the efficacy window many times, which indicates that segmentation delivery can increase the duration of the drug in the therapeutic effective range and thus may improve the therapeutic effect.



Fig. 5. the area of the locoregional drug concentration-time curve within the therapeutic windows

4 Conclusion

This study explored different drug delivery routes inspired by MC to enhance therapeutic outcomes. Analysis revealed that drug delivery through pathways one and two, which feature two branches, facilitates the diffusion and absorption of the drug before reaching the lesion site, leading to a more uniform drug distribution and a more stable therapeutic effect. Although path three offers rapid drug delivery, its lack of uniform distribution might compromise efficacy. Additionally, this research introduces waveform modulation to precisely control drug concentrations at targeted lesion sites. This strategy optimizes the therapeutic window by modulating drug release rates temporally and spatially to simulate specific concentration-time curves. This approach ensures precise control over drug concentration peaks and durations, maximizing efficacy while minimizing side effects. Overall, the optimization of paths one and two, combined with waveform modulation strategies, offers a new perspective on improving the precision and safety of drug therapy, paving the way for dynamically tailored treatment plans based on each patient's unique conditions.

References

1. Chude-Okonkwo, U.A., Malekian, R., Maharaj, B.T., Vasilakos, A.V.: Molecular communication and nanonetwork for targeted drug delivery: a survey. IEEE Commun. Surv. Tutorials **19**(4), 3046–3096 (2017)
2. Wilhelm, S., et al.: Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. **1**(5), 1–12 (2016)
3. Akyildiz, I.F., Brunetti, F., Blázquez, C.: Nanonetworks: a new communication paradigm. Comput. Netw. **52**(12), 2260–2279 (2008)

4. Chahibi, Y., Pierobon, M., Song, S.O., Akyildiz, I.F.: A molecular communication system model for particulate drug delivery systems. IEEE Trans. Biomed. Eng. **60**(12), 3468–3483 (2013)
5. Salehi, S., Moayedian, N.S., Assaf, S.S., Cid-Fuentes, R.G., Solé-Pareta, J., Alarcón, E.: Releasing rate optimization in a single and multiple transmitter local drug delivery system with limited resources. Nano Commun. Netw. **11**, 114–122 (2017)
6. Sun, Y., Zhang, R., Chen, Y.: A molecular communication detection method for the deformability of erythrocyte membrane in blood vessels. IEEE Trans. Nanobiosci. **20**(4), 387–395 (2021)
7. Sun, Y., Liu, M., Xiao, Y., Chen, Y.: A novel molecular communication inspired detection method for the evolution of atherosclerosis. Comput. Methods Programs Biomed. **219**, 106756 (2022)
8. Hopfenberg, H.B.: Controlled release from erodible slabs, cylinders, and spheres (1976)
9. Farsad, N., Yilmaz, H.B., Eckford, A., Chae, C.B., Guo, W.: A comprehensive survey of recent advancements in molecular communication. IEEE Commun. Surv. Tutorials **18**(3), 1887–1919 (2016)
10. Krause, A., Lott, D., Dingemanse, J.: Estimation of attainment of steady-state conditions for compounds with a long half-life. J. Clin. Pharmacol. **61**(1), 82–89 (2021)
11. Muller, P.Y., Milton, M.N.: The determination and interpretation of the therapeutic index in drug development. Nat. Rev. Drug Discovery **11**(10), 751–761 (2012)
12. Zhou, Y., Chen, Y.: Latticed channel model of touchable communication over capillary microcirculation network. IEEE Trans. Nanobiosci. **18**(4), 669–678 (2019)
13. Felicetti, L., Femminella, M., Reali, G.: Directional receivers for diffusion-based molecular communications. IEEE Access **7**, 5769–5783 (2018)
14. Wang, D., Sun, Y., Xiao, Y., Chen, Y. : An optimal strategy for individualized drug delivery therapy: a molecular communication inspired waveform design perspective. In: 43rd Annual International Conference of the IEEE Engineering in Medicine Biology Society (EMBC), pp. 866–869. IEEE, Mexico (2021)
15. Wang, P., Kelly, C., Harvey, A., Qayum, N., Muschel, R. J., Brady, M. : Quantitative analysis of tumor vascular structure after drug treatment. In: 32nd Annual International Conference of the IEEE Engineering in Medicine and Biology, pp. 726–729. IEEE, Argentina (2010)